Low-Calorie Diet in People With Prediabetes/Metabolic Syndrome

Obesity Clinical Trial

— CALIBRATE  

Official title:

Metabolic, Multi-organ and Microvascular Effects of a Low-calorIe Diet in Younger Obese With Prediabetes and/or Metabolic Syndrome

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04786418
• Other study ID #: UoL001431
• Status: Not yet recruiting
• Phase: N/A
• Start date: April 2021
• Est. completion date: December 2024

Study information

• Verified date: March 2021
• Source: University of Liverpool
• Contact: Daniel Cuthbertson
• Phone: 01515295940
• Email: Dan.Cuthbertson[@]liverpool.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Significant weight reduction, achieved by low-calorie diet (LCD), will mobilise ectopic fat (visceral and particularly liver fat), improving insulin sensitivity and other metabolic syndrome components, with secondary beneficial effects on cardiac structure and function.

This CALIBRATE study (metabolic, multi-organ and effects of low-calorie diet in younger obese patients with pre-diabetes) will compare the effects of a safe and effective 12-month weight management intervention, initially using a low-calorie, liquid replacement diet for 12 weeks, anticipating at least 10% reduction in body weight. The investigators will examine how much the weight loss improves the metabolic abnormalities that precede type 2 diabetes (T2D), and in reversing the pre-clinical/subtle clinical abnormalities of the liver and heart that precede liver and cardiovascular disease (CVD).

This study will compare the effects of a safe and effective 12-month weight management intervention, initially using a low-calorie, liquid replacement diet for 12 weeks, followed by a weight maintenance phase. The investigators will examine how much the weight loss improves the metabolic and neuropathic abnormalities that precede and accompany type 2 diabetes (T2D), and in reversing the pre-clinical/subtle clinical abnormalities of the liver and heart that precede liver and cardiovascular disease. In an additional optional sub-study, the investigators will additionally assess how the weight loss impacts upon appetite regulation within the brain with functional MRI (fMRI).

Description:

Prediabetes affects up to 35% of the population. It is defined as an intermediate metabolic state of glucose dysregulation between normoglycaemia and type 2 diabetes (T2D). Prediabetic individuals have 3-12 times higher annual incidence of type 2 diabetes than the general population. Further, these individuals have a considerable increased risk of cardiovascular disease (CVD), (myocardial infarction, stroke, CV death) and even in the absence of coronary artery disease, an increased risk of heart failure. Individuals with prediabetes manifest the same clustering of cardiovascular risk factors (dysglycaemia, dyslipidaemia, hypertension, obesity, physical inactivity, insulin resistance, pro-coagulant state, endothelial dysfunction, inflammation) that confer the high risk for macrovascular complications in type 2 diabetes. For example, 37% and 51% of individuals with prediabetes have hypertension and dyslipidaemia.

Results of large randomised control trials focusing on diabetes management have shown improvements in cardiovascular and renal outcomes and treatments for patients with established type 2 diabetes. Studies examining cardiovascular and renal burdens in patients with prediabetes have demonstrated that the same therapeutic benefits have not been observed in adults with prediabetes. This study focuses on a younger age group considering the aggressive phenotype of young-onset type 2 diabetes as it provides the opportunity to address and effectively manage the associated cardio-metabolic risk factors, prevent progression from prediabetes to type 2 diabetes and reduce the burden of cardiovascular disease, heart failure and liver-related burden.

Liver fat predicts both cardiovascular disease and type 2 diabetes independent of obesity. NAFLD is a growing clinical problem which has become the most prevalent chronic liver disease in Western society. It can be associated with isolated hepatic triglyceride accumulation (steatosis), through steatosis plus hepatocellular damage with inflammation and fibrosis (non-alcoholic steatohepatitis (NASH), which may ultimately progress to liver fibrosis/cirrhosis and hepatocellular carcinoma.

Non-Alcoholic Fatty Liver Disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome and is commonly associated with insulin-resistant states including obesity, a higher prevalence of prediabetes and type 2 diabetes (T2D).

NAFLD has a bi-directional relationship with prediabetes and T2D being a risk factor for Non-Alcoholic Fatty Liver Disease but conversely, individuals with prediabetes and type 2 diabetes have significantly increased liver fat versus non-diabetic control subjects with a higher risk of NAFLD than Body Mass Index (BMI) -matched non-diabetic controls.

NAFLD is associated with a metabolic phenotype similar to that observed in T2D: hepatic and peripheral insulin resistance with reduced skeletal muscle glucose uptake and increased non-esterified fatty acid (NEFA) release from adipose tissue lipolysis. Once liver fat accumulates in the liver, insulin is unable to inhibit glucose and very-low-density lipoprotein (VLDL) production resulting in overproduction of glucose and very-low-density lipoprotein (VLDL) particles leading to hypertriglyceridaemia and low high-density lipoprotein (HDL)-cholesterol concentrations.

NAFLD is associated with an increased risk of cardiovascular disease with CVD now representing the leading cause of death in NAFLD. While it remains contentious whether the increased risk of CVD in NAFLD is explained by the combination of common risk factors shared by both NAFLD and CVD, most epidemiological studies evaluating CVD risk in NAFLD suggest the risk occurs independently of associated risk factors. These studies have relied upon biochemical and imaging surrogate markers of NAFLD (e.g. serum liver enzymes, abdominal ultrasound). Using more detailed assessment of NAFLD e.g. assessment of fibrosis with fibrosis panels, with Magnetic Resonance Imaging (MRI) or even biopsy-based.

Clinical studies have shown that sustained moderate weight loss of around 5-10%, achieved through lifestyle intervention lowers blood pressure, improves glucose control, prevents diabetes, and improves dyslipidaemia, as well as improving haemostatic and fibrinolytic factors. The effects of weight reduction on progression to T2D has been studied in pre-diabetes in the Diabetes Prevention Programme study (US) study. A 1 kg of weight loss is associated with a 16% reduction in the progression of pre-diabetes to T2D.

Metabolic surgery is associated with remission of T2D. There is overwhelming evidence that LCDs have a useful role in T2D resulting in substantial weight loss (mean difference in weight vs. controls after 3 months was 7.38 kg (CI: 16.2, 1.5) with high levels of adherence. They can potentially cause profound weight loss of 15-20% of body weight in severe and medically complicated obesity. The weight loss is associated with significant reductions in hepatic and pancreatic fat with associated improvements in insulin sensitivity and pancreatic ß-cell function resulting in remission of T2D in many cases. This dramatic dietary intervention, initially believed to be unmanageable and difficult to maintain, has been demonstrated to be implementable and highly efficacious even when delivered through primary care settings.

In one primary care study, using LCD in T2D patients recorded a weight loss of 15kg or more in 24% of patients after 12 months. It is unsurprising that 46% of the participants achieved remission of their T2D. LCD produces bariatric type weight loss and improves glycaemic control in diabetes and results in remission of T2D in the majority of patients, however the impact on complications, remains to be determined particularly in obese people without diabetes. One non-pharmacological strategy to improve cardio-metabolic health in obesity, pre-diabetes and type 2 diabetes mellitus (T2DM) includes the application of a low-calorie diet (LCD), utilising reduced daily energy intake (<800kcal).

To this extent, the purpose of this study is to examine the impact of intensive weight management on metabolic, liver and cardiac health, measures on neuropathy and on appetite regulation. The investigators will study younger (<55y) obese people with pre-diabetes and/or metabolic syndrome who exhibit early or pre-clinical evidence of metabolic and cardiovascular complications. The investigators will investigate the effects of a low-calorie diet (LCD) as one of the most effective and least invasive mechanism by which these various factors can be improved.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 44
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• The investigators shall recruit participants with the following characteristics:

• Men and women

• aged 18-55 years*,

• BMI 30-40 kg/m2 , BMI>27 kg/m2 for Chinese/South Asians

• Any one of the following three metabolic criteria:

1. a diagnosis of prediabetes (HbA1c 42-47 mmol/mol), OR

2. NAFLD (based on fatty liver index, FLI >60). FLI will be determined using waist circumference, BMI, serum triglyceride and GGT (gamma-glutamyltransferase). OR

3. a diagnosis of metabolic syndrome using the IDF metabolic syndrome criteria (see below,

Exclusion criteria:

• Individuals with normal glucose tolerance (NGT) or type 1 or type 2 diabetes (T2D).

• Anyone engaged in active weight loss (>5kg weight loss in the last 6 months), currently engaged with weight management service, previous bariatric surgery, on weight-lowering medications (e.g. orlistat or liraglutide) or with a history of an eating disorder.

• planning pregnancy/6 months post-partum,

• known structural cardiac disease or anyone with major atherosclerotic disease

• history of stroke within the last 3 months

• Active mental health illness (e.g. severe depression, bipolar disorder, schizophrenia or other psychotic disorders). Use of drug with known major effects on bodyweight (e.g. corticosteroid, anti-psychotic, anticonvulsants etc).

• Planning pregnancy within the next 6 months and until >6 months post-partum or breastfeeding

• Substance abuse e.g. drugs/alcohol.

• Eating disorder, previous bariatric surgery, currently taking weight loss drugs or already engaged with weight management service

• Learning difficulties

• A contraindication to magnetic resonance scanning will exclude the patient from the MRI component of the study

Related Conditions & MeSH terms

• Fatty Liver
• Glucose Intolerance
• Metabolic Syndrome
• NAFLD
• Obesity
• Pre Diabetes
• Prediabetic State
• Syndrome

Intervention

Other:
• Standard of care
Participants allocated to the control group will be given standard clinical information regarding healthy eating, physical activity and management of weight, in line with current NHS practise.

Dietary Supplement:
• Low-calorie diet
The LCD intervention group, will received a well validated, commercially available, intensive weight management protocol Counterweight-Plus.

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
University of Liverpool	Perspectum, University of Surrey

References & Publications (1)

Leslie WS, Ford I, Sattar N, Hollingsworth KG, Adamson A, Sniehotta FF, McCombie L, Brosnahan N, Ross H, Mathers JC, Peters C, Thom G, Barnes A, Kean S, McIlvenna Y, Rodrigues A, Rehackova L, Zhyzhneuskaya S, Taylor R, Lean ME. The Diabetes Remission Clin — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in liver fat >5 percent, determined by MRI, from baseline to after 12 months of intervention.	For liver fat, diagnosis of NAFLD is based on a threshold of a value >5.5 percent. The investigators anticipate having a 45 percent difference in the proportion in whom liver fat percentage reduces by at least 5 percent between the groups (50 percent of LCD will have an absolute reduction in liver fat of 5 percent vs. 5 percent of controls). The investigators chose an absolute reduction of liver fat of 5 percent as this reduction is clinically meaningful.	Changes will be measured at baseline and at 12 months.
Secondary	Body Mass Index	Weight (kg) and height (cm) to measure body mass index (BMI) and to assess the changes in body mass index (BMI).	Changes will be measured at baseline and at 12 months.
Secondary	Body weight	Body weight (kg) and to assess the changes in body weight (kg).	Changes will be measured at baseline and at 12 months.
Secondary	Waist Circumference	To access changes of waist circumference that is correlated with visceral (abdominal) adiposity (cm).	Changes will be measured at baseline and at 12 months.
Secondary	Blood pressure	Systolic and Diastolic (mmHg)	Changes will be measured at baseline and at 12 months.
Secondary	Liver biochemistry: Alanine transaminase	To access liver function tests of ALT (u/L).	Changes will be measured at baseline and at 12 months.
Secondary	Changes in HbA1c	Changes of HbA1c of 6 mmol/mol in approximately 50 percent of the LCD intervention group vs. 5 percent in the control group. The investigators believe the application of thresholds in looking at the changes in HbA1c are justified based on the diagnostic thresholds used in the diagnosis of normal glucose tolerance (NGT) (HbA1c<42 mmol/mol), prediabetes (42-47 mmol/mol) and type 2 diabetes (T2D) (>48 mmol/mol). By using a threshold of HbA1c reduction of 6 mmol/mol, all participants, irrespective of their baseline HbA1c would have remission of prediabetes to NGT. The investigators avoided categorising individuals as moving from prediabetes to NGT would capture small changes in HbA1c that were less clinically significant (e.g. an individual who goes from 43 to 41 mmol/mol).	Changes will be measured at baseline, at 12 weeks, at 24 week and at 12 months.
Secondary	Lipid profile	LDL, HDL, total cholesterol and triglycerides (mmol/L)	Changes will be measured at baseline and at 12 months.
Secondary	Metabolic measures of fatty liver	Fatty liver index (FLI) score: <30/Low/Fatty liver ruled out (LR- = 0.2); 30 to <60/Indeterminate/Fatty liver neither ruled in nor ruled out; =60/High/Fatty liver ruled in (LR+ = 4.3)	Changes will be measured at baseline and at 12 months.
Secondary	Markers of fibrosis in liver	FIB-4 Score (Approximate fibrosis stage*) <1.45 = 0-1; 1.45-3.25 = 2-3; 3.25 = 4-6	Changes will be measured at baseline and at 12 months.
Secondary	The NAFLD scoring screening tool	NAFLD fibrosis score; = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×109/l) - 0.66 × albumin (g/dl).; < -1.455: predictor of absence of significant fibrosis (F0-F2 fibrosis) = -1.455 to = 0.675: indeterminate score 0.675: predictor of presence of significant fibrosis (F3-F4 fibrosis)	Changes will be measured at baseline and at 12 months.
Secondary	Peripheral insulin sensitivity	Oral Glucose Tolerance Test (mmol/L)	Changes will be measured at baseline and at 12 months.
Secondary	Changes in hepatic insulin sensitivity	Hepatic insulin sensitivity	Changes will be measured at baseline and at 12 months.
Secondary	Changes in insulin secretion	Pancreatic beta cell function	Changes will be measured at baseline and at 12 months..
Secondary	Changes in fatty acid metabolism	Fatty acid handling	Changes will be measured at baseline and at 12 months.
Secondary	Measures of neuropathy: Change in intra-epidermal nerve fibres densities, length and branch densities.	Change in corneal nerve fibre density (CNFD) - Number of major nerves/ mm2 of corneal tissue.; Change in corneal nerve fibre length (CNFL) - Length of nerves/ mm2 of corneal tissue.; Change in corneal nerve branch density (CNBD) - Number of nerve branches/mm2 of corneal tissue.	Changes will be measured at baseline and at 12 months.
Secondary	Measures of neuropathy: Change in sural nerve velocity	Velocity (m/s)	Changes will be measured at baseline and at 12 months.
Secondary	Measures of neuropathy: Change in sural nerve amplitude	Amplitude (mV)	Changes will be measured at baseline and at 12 months.
Secondary	Functional MRI	Changes in brain signals in response to food cues	Changes will be measured at baseline and at 12 months.
Secondary	Appetite measurement	Visual Analog Score for Appetite: Scale range from 0 to 10 (not at all to extremely); Hungry : 0 (Not at all hungry) - 10 (Extremely hungry); Fullness: 0 (Not at all full) - 1- (Extremely full); Satisfied: 0 (Not at all satisfied) - 10 (Extremely satisfied); Strong desire to eat: 0 (not at all strong) - 10 (Extremely strong); How much food you could eat : 0 (Not at all) - 10 (a large amount); Thirsty: 0( not at all thirsty) - 10 (Extremely thirsty); Nauseous: 0 (not at all nauseous) - 10 (Extremely nauseous)	Changes will be measured at baseline and at 12 months.
Secondary	MRI-derived fat volumes	Subcutaneous and visceral fat content (litres)	Changes will be measured at baseline and at 12 months.
Secondary	Cardiac structure (volumes)	Cardiac chamber volumes at various phases in cardiac cycle (LVESV, LVEDV)	Changes will be measured at baseline and at 12 months.
Secondary	Cardiac health: cardiac magnetic resonance imaging	LV mass (g)	Changes will be measured at baseline and at 12 months.
Secondary	Cardiac health: LV Mass Indexed to Body Surface Area	LV Mass Indexed to Body Surface Area (g/m2)	Changes will be measured at baseline and at 12 months.
Secondary	Cardiac health: Multi-parametric cardiac MRI	LV Mass: volume ratio (LVM/LVEDV)	Changes will be measured at baseline and at 12 months.
Secondary	Changes in early diastolic strain rate by cardiovascular magnetic resonance	Peak early diastolic strain rate (s-1)	Changes will be measured at baseline and at 12 months.
Secondary	Changes in load and contractility of the cardiac function	Peak systolic strain (percent)	Changes will be measured at baseline and at 12 months.
Secondary	Charcterisation of organ fat content	Liver, pancreas, kidney, skeletal muscle	Changes will be measured at baseline and at 12 months.
Secondary	Multi-organ MRI measure for pancreas, spleen and kidney	Fibrosis score cT1 (ms)	Changes will be measured at baseline and at 12 months.
Secondary	Multi organs pancreas, spleen and kidney volume	Volumes (cm3)	Changes will be measured at baseline and at 12 months.
Secondary	Multi organs pancreas, spleen and kidney fat content	Fat content (percent)	Changes will be measured at baseline and at 12 months.